Navigation Links
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
Date:5/31/2011

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection with enterohemorrhagic Escherichia coli (EHEC). The infections occurred in 2010. EHEC are the bacteria that cause the current wave of infections that have already claimed ten lives in Germany. The number of suspected and confirmed cases of EHEC has now reached 700.

Eculizumab has been approved in Germany since 2007 and is used to treat a rare blood disease and a rare congenital form of HUS. Two years ago, American physicians reported similar success in children with this form of HUS (NEJM 2009; 360:544-546).

The children suffered from kidney failure and severe neurological disorders. "After several exchanges of blood plasma had no effect, we decided to attempt treatment with Eculizumab," reports Professor Dr. Franz Schaefer, head of the section of Pediatric Nephrology at the Center for Child and Adolescent Medicine at Heidelberg University Hospital.

Within 24 hours of the initial infusion, which was repeated once or twice at intervals of seven days, the clinical condition of the children improved dramatically. Dialysis due to acute kidney failure from HUS could be discontinued. All three children recovered and had no sequelae even six months after the illness.

The researchers decided on using the monoclonal antibody Eculizumab as it interrupts the destructive immune reactions that occur after an infection with EHEC. Eculizumab binds to protein C5, which activates what is called the complement cascade and lead to the destruction of blood cells among other things. With EHEC infections there can also be complement activation, triggered by the Shiga toxin formed by the bacteria.

"We now hope that these results will help the acutely ill patients," said Professor Schaefer. He assumes that even adult patients can profit from therapy with the antibody. "Because of the epidemic in Germany, the publishers of the New England Journal of Medicine decided to accelerate the publishing date of the article, which they have had since February, and they published it immediately after reviewing it," said Schaefer. In addition, the article was sent to all kidney specialists in Germany.

Meanwhile, first treatments of adults and children in German hospitals have started. The German Society of Nephrologists has issued guidelines that the antibody may be given if all others standard treatments like dialysis and plasmapheresis have failed.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
49-622-156-4536
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Accurate interpretation of antinuclear antibodies test key to confirming autoimmune disease
2. Why so many antibodies fail to protect against HIV infection
3. Novel autoantibodies identified in patients with necrotizing myopathy
4. Manmade antibodies hold biomedical promise
5. Antibodies linked to cardiovascular disease increase in patients with active lupus
6. Low levels of natural antibodies behind stroke
7. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
8. Cryoablation used to successfully treat atrial fibrillation at the Montreal Heart Institute
9. Successful depression treatment of mothers has long-term effects on offspring
10. Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes
11. Successful Schools May Help Keep Kids Out of Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: